Chartwell Partners is pleased to announce that, following a targeted board search process, Zeenat Sidi has been appointed to the Board of Directors of Business First Bancshares, Inc. and its banking subsidiary, b1BANK. Sidi brings more than twenty‑five years of executive leadership experience across fintech, consumer banking, lending, payments, and digital transformation in the U.S….
Month: August 2024
Neuroscience biopharmaceutical company, Xenon Pharmaceuticals, has hired Matt Ronsheim, PhD, as its Chief Operating Officer where he will oversee CMC, Program Management and Quality Assurance. We are delighted to have recruited five executives to Xenon as the company continues its evolution towards the commercialization of its first product candidate. Dr. Ronsheim has 25 years of experience…
We are honored to continue our work with Protagonist Therapeutics, recruiting I&I R&D leader, Newman Yeilding, MD, as the Company’s Executive Vice President and Chief Scientific Advisor. Throughout his career, including 17 years with Janssen, Dr. Yeilding has successfully championed multiple novel programs through research, development and commercialization in rheumatology, gastroenterology, dermatology, and pediatrics. Dr….